PQA Receives NQF Endorsement of Three Performance Measures to Address Opioid Misuse/Abuse
Pharmacy Quality Alliance (05/10/2017)
Thirteen new measures related to patient safety have been endorsed by the National Quality Forum (NQF), including three Pharmacy Quality Alliance (PQA) measures that address the use of opioids at high dosage or from multiple providers. Use of Opioids at High Dosage in Persons Without Cancer (OHD) assesses populations who are receiving prescriptions for opioids at a high dose that could be inappropriate or could contribute to an adverse event. Another measure, titled Use of Opioids from Multiple Providers in Persons Without Cancer, assesses populations that are receiving opioid prescriptions from multiple prescribers and multiple pharmacies, which may indicate uncoordinated care and/or doctor/pharmacy shopping. The third PQA measure, Use of Opioids at High Dosage and from Multiple Providers in Persons Without Cancer, includes criteria of both high-dose opioids and also receiving prescriptions from multiple providers, which could be indicative of misuse, abuse, or inappropriate and/or fragmented care. The three measures currently are reported by the Centers for Medicare & Medicaid Services (CMS) to Part D prescription drug plans through the CMS Patient Safety reports, and CMS has proposed the measures be included on the 2019 Part D Display page. Additionally, the OHD measure is included in the 2016 Core Set of Adult Health Care Quality Measures for Medicaid (Adult Core Set).